



---

For additional information contact:  
Jody Donohue, APR  
Communications Manager  
Office: 913.945.4405  
Mobile: 913.333.6329  
Email: jody.donohue@ceva.com

---

## **Ceva Biomune Celebrates Completion of \$10MM Expansion in Lenexa**

**(Lenexa, Kan. – June 15, 2015)** Ceva Biomune has again expanded facilities to meet demand for its vaccine products. A \$10 million dollar expansion will allow the company to increase vaccine production capacity and utilize new technology in the process.

Products produced on the campus are sold both domestically and internationally. Vaccines produced in Lenexa are shipped to over 70 countries world-wide. Ceva has grown its export business from just 12 percent of sales in 2006 to nearly 70 percent of annual sales today. The number of employees working to produce vaccine has more than doubled in the past 10 years.

“Ceva is, and has always been, focused on aggressive growth here in Lenexa and around the world,” said Daryl Pint, CEO of Ceva Biomune. “Since 2005, Ceva has invested over \$65 million dollars in the Lenexa campus to support the growth of the vaccine market. Every 12 to 16 months we break ground on a new project to add additional space to meet growing demand for our vaccine.”

Ceva will break ground on a 35,000 square foot construction project later this summer. The new facility expected to come on line in 2017 will be part of a \$30 million investment in new construction and equipment.

“Ceva’s rapid growth speaks to the passion and commitment our employees bring to work every day,” said Pint. “Every day they give it their all and live Ceva’s values of entrepreneurship, innovation, team work and customer passion. We owe our success to our employees.”

Mike Boehm, Mayor of Lenexa, expressed his appreciation for Ceva’s investment in the city.

“The growth of this campus is exciting and good for the city of Lenexa. The steady record of job creation and consistent expansion means many dollars are at work here supporting our grocery stores, restaurants, car mechanics, and all the other types of businesses in our community,” said Boehm. “Ceva’s campus looks nothing like it did 10 years ago. Based on the company’s plans it is safe to say that it will look much different 10 years from now too.”

The new facility will be used to increase capacity in poultry vaccine for the time being. Later this year or early in 2016 swine vaccine production will begin taking place. Ceva announced late last year its intention to enter the U.S. swine vaccine market and is working toward licensing products for that industry.

*Continued*



---

For additional information contact:  
Jody Donohue, APR  
Communications Manager  
Office: 913.945.4405  
Mobile: 913.333.6329  
Email: [jody.donohue@ceva.com](mailto:jody.donohue@ceva.com)

---

“Ceva is known as a market leader for our superior customer service and innovation in vaccine production. This expansion will allow us to meet our goals of being the number one poultry vaccine provider both domestically and around the world. When we receive our licenses for swine products this new space will be critical in being able to scale up to support that business unit. Completing this expansion is just one more step toward Ceva’s goal of becoming a Top 5 global animal health company by 2020,” said Pint.

###

About Ceva Animal Health: Since Ceva acquired the Biomune Company in 2005, production capabilities have steadily grown. Ceva currently supplies more than 50 countries with critical poultry vaccines. This growth means we’re continually investing in production, research and development to offer novel vector and custom vaccines to our customers. The company’s North American headquarters is in Lenexa, Kansas. Visit [www.ceva.us](http://www.ceva.us).